United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 6,000 shares of the firm's stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $232.37, for a total value of $1,394,220.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company's stock, valued at approximately $8,530,302.70. The transaction was disclosed in a document filed with the SEC, which is available through this link.
United Therapeutics Stock Performance
NASDAQ UTHR opened at $233.93 on Friday. The stock has a 50-day simple moving average of $227.00 and a two-hundred day simple moving average of $227.69. The firm has a market capitalization of $11.01 billion, a P/E ratio of 11.79 and a beta of 0.52. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company's revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the business posted $2.67 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 23.46 earnings per share for the current year.
Hedge Funds Weigh In On United Therapeutics
4 coins to be the “Next Bitcoin”
From True Market Insiders | Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%...
Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
Institutional investors have recently modified their holdings of the stock. Atlas Capital Advisors LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $51,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 65 shares in the last quarter. GAMMA Investing LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $43,000. Neo Ivy Capital Management purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $48,000. Finally, Zions Bancorporation N.A. purchased a new position in shares of United Therapeutics in the 1st quarter valued at about $66,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on UTHR. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Wednesday. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They issued an "outperform" rating and a $330.00 price objective for the company. The Goldman Sachs Group raised United Therapeutics from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, Wells Fargo & Company lifted their price target on United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics has an average rating of "Buy" and an average price target of $294.40.
Check Out Our Latest Stock Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
